Long-term effects of Lactobacillus brevis CD2 and doxycycline on periodontitis
Journal name: Journal of Indian Society of Periodontology
Original article title: Long-term effect of Lactobacillus brevis CD2 (Inersan®) and/or doxycycline in aggressive periodontitis
The Journal of Indian Society of Periodontology (JISP) publishes original scientific articles on periodontology (the study of supporting structures of teeth) and oral implantology. It is a bimonthly open-access journal with special issues for specific occasions.
This page presents a generated summary with additional references; See source (below) for actual content.
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Mishal Piyush Shah, Sheela Kumar Gujjari, Veerendrakumar Siddhpur Chandrasekhar
Journal of Indian Society of Periodontology:
(A bimonthly open-access journal)
Full text available for: Long-term effect of Lactobacillus brevis CD2 (Inersan®) and/or doxycycline in aggressive periodontitis
Year: 2017 | Doi: 10.4103/jisp.jisp_215
Copyright (license): CC BY-NC-SA
Summary of article contents:
Introduction
The overuse of antibiotics has led to the emergence of resistant microorganisms and has adversely affected the indigenous microflora, such as Lactobacillus in the oral cavity. To address this issue, a randomized clinical trial was conducted to investigate the potential benefits of Lactobacillus brevis CD2 lozenges, with a hypothesis that these lozenges, either in isolation or combined with oral doxycycline, could improve periodontal health over five months in patients with aggressive periodontitis.
Probiotic Treatment and Its Implications
The study involved 18 nonsmoking patients aged between 14 and 35 years, all diagnosed with aggressive periodontitis. Participants received 14 days of treatment with either Lactobacillus brevis CD2 lozenges, Lactobacillus brevis CD2 lozenges plus doxycycline, or doxycycline alone. Clinical parameters, including the plaque index, gingival index, probing pocket depth, and microbiological measures of lactobacilli and Aggregatibacter actinomycetemcomitans, were assessed. Results indicated that all treatment groups experienced improvements in clinical measures, particularly a significant reduction in the gingival index. The probiotic lozenges were found to maintain higher concentrations of lactobacilli over five months, suggesting their potential role as an alternative treatment when compared to traditional antibiotics, which may result in less disruption to the body’s microflora.
Conclusion
In summary, the findings from this study indicate that a 14-day regimen of Lactobacillus brevis CD2 lozenges has a long-lasting positive impact on the clinical parameters associated with aggressive periodontitis, particularly in terms of gingival health. The effects observed were comparable to those of doxycycline, with the added benefit of sustaining beneficial lactobacilli levels without the risks associated with antibiotic resistance. This research supports the use of probiotics as a viable alternative in managing periodontal diseases.
FAQ section (important questions/answers):
What was the main aim of the study on Lactobacillus brevis?
The study aimed to test if 14 days of treatment with Lactobacillus brevis CD2 lozenges, either alone or with doxycycline, would improve periodontal health after a follow-up period of 5 months.
How many patients participated in the clinical trial?
Eighteen nonsmoking patients aged 14–35 with aggressive periodontitis participated in the randomized clinical trial, which assessed various treatments over a span of 5 months.
What clinical parameters were assessed during the study?
Clinical parameters measured included plaque index, gingival index, probing pocket depth, and clinical attachment level, enabling the evaluation of periodontal health over time.
What were the key findings regarding Lactobacillus and doxycycline?
The study found that Lactobacillus brevis CD2 lozenges showed significant improvements in the gingival index similar to doxycycline, suggesting that probiotics could effectively manage aggressive periodontitis.
What was the general conclusion of the study regarding antibiotics?
The study concluded that probiotics like Lactobacillus brevis could be used as alternatives to antibiotics, reducing risks of antibiotic resistance and preserving the body’s microflora.
Glossary definitions and references:
Scientific and Ayurvedic Glossary list for “Long-term effects of Lactobacillus brevis CD2 and doxycycline on periodontitis”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.
1) Table:
Table refers to an organized presentation of data that allows for easy comparison and analysis of clinical parameters over time in the study. In this context, it specifically showcases the results at baseline and after 5 months, highlighting numerical improvements in patient health indicators after treatment with different interventions.
2) Study (Studying):
Study represents the structured investigation conducted to examine the effectiveness of different treatments for periodontal health. This randomized clinical trial aimed to analyze the benefits of Lactobacillus brevis CD2 lozenges both alone and in combination with doxycycline, offering insights into alternative therapies in addressing aggressive periodontitis.
3) Antibiotic (Antibacterial):
Antibiotic is a term for a class of medicinal drugs used to treat bacterial infections. In this study, doxycycline, an antibiotic, was assessed for its effects alongside probiotics. The relevance of antibiotics is crucial, as the overuse can lead to resistance, prompting the exploration of alternative treatments like probiotics.
4) Visit:
Visit refers to the appointments or scheduled assessments during the study where patient data was collected. Multiple visits were key in evaluating changes in clinical parameters over time, allowing researchers to track the long-term effects of treatments and the progression or improvement of periodontal health in participants.
5) Sah:
Shah is the surname of the lead author of the study, who conducted previous research on the topic. Mentioning Shah highlights the credibility and prior knowledge established in the field of probiotics and periodontal disease, reinforcing the authority of the findings reported in this particular randomized clinical trial.
6) Discussion:
Discussion is the section of the study where the authors interpret their findings, connect back to the original hypothesis, and elaborate on the implications of the results. It serves to contextualize the study data, comparing it to existing literature and explaining the significance of the results for clinical practices.
7) Food:
Food in this context refers to Lactobacillus brevis CD2, a probiotic that is a food product containing live microorganisms beneficial to health. The study evaluates the impact of this probiotic 'food' on periodontal health, suggesting a potential role of dietary components in preventing or treating aggressive periodontitis.
8) Drug:
Drug refers to any substance intended for use in the diagnosis, cure, treatment, or prevention of disease. In this study, doxycycline is identified as a drug used to treat infections, while discussing its use alongside probiotics. It emphasizes the need for alternatives in pharmaceuticals, particularly addressing antibiotic resistance issues.
Other Health Sciences Concepts:
Discover the significance of concepts within the article: ‘Long-term effects of Lactobacillus brevis CD2 and doxycycline on periodontitis’. Further sources in the context of Health Sciences might help you critically compare this page with similair documents:
Statistical analysis, Randomized clinical trial, Plaque index, Gingival index, Oral cavity, Aggregatibacter actinomycetemcomitans, Microbiological parameters, Probing pocket depth, Microbiological analysis, Clinical attachment level, Clinical parameter, Resistant microorganisms, Oral doxycycline.